Can the publication of guidelines change the management of early rheumatoid arthritis? An interrupted time series analysis from the United Kingdom.

OBJECTIVE To assess whether publication of national treatment guidelines improved the management of early RA in the UK. METHODS Incident diagnoses of RA in persons aged over 18 years from 1995 to 2010 were identified from the Clinical Practice Research Datalink. Using a natural experimental study design, interrupted time series analysis was used to assess whether trends in the proportion of patients receiving DMARDs, within 3 and 12 months of diagnosis, changed following publication of British Society for Rheumatology guidelines in 2006. RESULTS Between 1995 and 2010, 11 772 incident cases of RA were identified. There was a progressive increase in the proportion of patients prescribed any DMARD within 12 months from 43.3% in 1995 to 78.5% in 2010. After publication of the British Society for Rheumatology guidelines, the proportion of patients prescribed any DMARD within 12 months increased by 4.2% (P = 0.053). Prior to the guidance, prescribing was increasing by 1.64% per year, compared with 3.55% per year after publication (P < 0.001). CONCLUSION Guidelines published by a national body can improve the proportion of patients receiving DMARD treatment in the first year after diagnosis of RA.

[1]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[2]  M. Cowie National Institute for Health and Care Excellence. , 2015, European heart journal.

[3]  Helena Canhão,et al.  FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries , 2014 .

[4]  Désirée van der Heijde,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update , 2013, Annals of the rheumatic diseases.

[5]  Seoyoung C. Kim,et al.  Changes in Use of Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States During 1983–2009 , 2013, Arthritis care & research.

[6]  N. Arden,et al.  Regional and temporal variation in the treatment of rheumatoid arthritis across the UK: a descriptive register-based cohort study , 2012, BMJ Open.

[7]  T. Pincus,et al.  Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis , 2012, Annals of Internal Medicine.

[8]  M. Petticrew,et al.  Using natural experiments to evaluate population health interventions: new Medical Research Council guidance , 2012, Journal of Epidemiology & Community Health.

[9]  Jeffrey R Curtis,et al.  2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis , 2012, Arthritis care & research.

[10]  C. Bombardier,et al.  Quality care in seniors with new‐onset rheumatoid arthritis: A Canadian perspective , 2011, Arthritis care & research.

[11]  G. Jürgens,et al.  Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. , 2010, Arthritis and rheumatism.

[12]  D. Huscher,et al.  Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the National Database of the German Collaborative Arthritis Centres , 2010, Annals of the rheumatic diseases.

[13]  D. M. van der Heijde,et al.  Extended Report , 2022 .

[14]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[15]  Zoe Stableford,et al.  Guidelines British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis ( after the first 2 years ) , 2009 .

[16]  L. Smeeth,et al.  How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? , 2008, Arthritis and rheumatism.

[17]  D. Symmons,et al.  Health state utility values: a description of their development and application for rheumatic diseases. , 2008, Arthritis and rheumatism.

[18]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[19]  J. Bridges,et al.  Charting the possible impact of national guidelines on the management of rheumatoid arthritis , 2008, Scandinavian journal of rheumatology.

[20]  A. Hingorani,et al.  British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. , 2007, Rheumatology.

[21]  M. Liang,et al.  Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. , 2006, Arthritis and rheumatism.

[22]  N. Goodson,et al.  British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). , 2006, Rheumatology.

[23]  Diane Lacaille,et al.  Gaps in care for rheumatoid arthritis: a population study. , 2005, Arthritis and rheumatism.

[24]  Craig R Ramsay,et al.  INTERRUPTED TIME SERIES DESIGNS IN HEALTH TECHNOLOGY ASSESSMENT: LESSONS FROM TWO SYSTEMATIC REVIEWS OF BEHAVIOR CHANGE STRATEGIES , 2003, International Journal of Technology Assessment in Health Care.

[25]  A. Gibofsky American College of Rheumatology. , 2002, Journal of the Medical Association of Georgia.

[26]  J. Wong,et al.  Long-term morbidity, mortality, and economics of rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[27]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.